Skip to content
PHARMACEUTICAL PREPARATIONS · SMALL CAP

Avricore Health Inc. AVCRF

10 fiscal years on record · CAD · FY2024 reported · SEC filings only
CAD 4.7M
▲ 33.7% YoY
CAD -668,977
CAD 823,521

Slide the table for earlier years · "·" marks a figure not available in our data for that year.

In brief

What this company does

Through its flagship offering HealthTab™ (a wholly owned subsidiary), it provides a turnkey point-of-care testing platform, creating value for stakeholders and better outcomes for patients. This is all possible thanks to the Company’s HealthTab™ technology, which provides lab-accurate results for specific blood work within 12 minutes. The Company is also in late-stage discussions with other Canadian and international major pharmacy chains, and has a strong prospect list for future expansion.

Written from the business description in Avricore Health Inc.'s annual report to the U.S. Securities and Exchange Commission, filed 16 June 2025. Every sentence was checked against that document before publication.

Growth

CAD 4.7M
Revenue, FY2024 · full 10-year series below
Revenue CAD M Net income CAD M
FY2024 · Revenue 4.7 · Net income -0.7
2M4M-2M-3M
2014201820212024
Compound annual growth
+236.0%
3 yrs
5 yrs
10 yrs
15 yrs

Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.

Profitability

−14 cents
lost on every revenue dollar
Operating margin Net margin
FY2024 · Net -14.4%
-500%-1000%
201420192024
ROE
FY2024 · ROE -33.6%
-100%-200%
201420192024
Three returns, three denominators.
Return on capital employedNot available: we don't have total assets or current liabilities for this period.

Each CAD of equity lost 34 cents this year.

Cash & shareholders

·
returned in FY2024 · dividends + net buybacks
Free cash flow CAD M
FY2024 · FCF 0.8
0.3M0.6M-1.0M-2.0M
201420192024

Total assetsCAD 2.3M
CashCAD 1.1M
DepositsCAD 12,000.00

Not available: we don't have the total debt figure for this period.

The 10-year record

10 fiscal years
Every figure from documents filed with the SEC · CAD

EPS, diluted, dividend per share and shares outstanding are shown without shading, and a vertical line marks the year the share count changed — the series crosses a large, unexplained change in share count, so the years on either side are not on a comparable scale.

row low → row highnegative—not applicable◌not available in our data
AVCRF, 10-year financial record
Metric 2024202320222021202020192018201720162014
Revenue CAD B0.00.00.00.00.0◌0.00.00.00.0
Operating income CAD B◌◌◌◌◌◌◌◌◌◌
EBITDA CAD B◌◌◌◌◌◌◌◌◌◌
Income tax CAD B◌◌◌◌◌◌◌◌◌◌
Net income CAD B−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0
Free cash flow CAD B0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0
EPS, diluted CAD −0.01−0.01−0.01−0.02◌◌◌◌◌◌
Dividend / sh CAD ◌◌◌◌◌◌◌◌◌◌
Payout % — not applicable: no dividend——————————
ROE %−33.6−35.3−39.3———−244.5−123.9−136.3−65.6

Slide the table for earlier years. "—" not applicable · "◌" not available in our data.

Compare

This company against its peers

More in this sector

Other companies filing in the same sector

Provenance

Company facts, as filed

How we verify · 0 failures · 4 divergences in 43 reconciliationsAUDITED

Reconciled in 6 of the 10 fiscal years we could check. 4 of those reconciliations are divergences — the figures exist but don't fit the formula this check expects; that isn't the same as an error. 18 checks were skipped: the balance sheet is not tagged before 2016. 12 checks were skipped: EPS is not tagged before 2019. Seven checks were skipped: revenue is not tagged before 2014.

EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidityCurrency consistency0 failures4 divergent
ActivityPharmaceutical Preparations
Listed onnot stated in the filings
Incorporated inoutside the United States — SEC code A1
Fiscal year endsDecember 31
Data on record since2014

Share this section

Download image